Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Kamila Buzun, Anna Bielawska, Krzysztof Bielawski & Agnieszka Gornowicz. (2020) DNA topoisomerases as molecular targets for anticancer drugs. Journal of Enzyme Inhibition and Medicinal Chemistry 35:1, pages 1781-1799.
Read now
Read now
Flavia Cochera, Daniel Dinca, Diana Aurora Bordejevic, Ioana Mihaela Citu, Adelina Marioara Mavrea, Minodora Andor, Mihai Trofenciuc & Mirela Cleopatra Tomescu. (2018) Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer. Cancer Management and Research 10, pages 2071-2081.
Read now
Read now
Ya-Di Wang, Yang Zhang, Bo Sun, Xiao-Wei Leng, Ya-Juan Li & Li-Qun Ren. (2018) Cardioprotective effects of rutin in rats exposed to pirarubicin toxicity. Journal of Asian Natural Products Research 20:4, pages 361-373.
Read now
Read now
Alexandra Pender & Robin L Jones. (2017) Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma. Clinical Pharmacology: Advances and Applications 9, pages 159-164.
Read now
Read now
Pier Luigi Zinzani, Massimo Federico, Stefano Oliva, Antonello Pinto, Luigi Rigacci, Giorgina Specchia, Alessandra Tucci & Umberto Vitolo. (2015) The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. Leukemia & Lymphoma 56:1, pages 12-25.
Read now
Read now
Articles from other publishers (43)
Danzhi Ying, Xin Shen, Shuqi Wang, Junyi Chen, Zhenying Wu, Wenteng Chen, Fudi Wang, Junxia Min & Yongping Yu. (2024) Discovery of 4-hydroxyl pyrazole derivatives as potent ferroptosis inhibitors. European Journal of Medicinal Chemistry 263, pages 115913.
Crossref
Crossref
Niloofar Deravi, Narges Norouzkhani, Kimia Keylani, Seyedeh Mona Haghi & Seyyed Kiarash Sadat Rafiei. 2024. Encyclopedia of Toxicology. Encyclopedia of Toxicology
519
531
.
Brandon M. Murareanu, Noelle V. Antao, Winnie Zhao, Aurore Dubuffet, Hicham El Alaoui, Jessica Knox, Damian C. Ekiert, Gira Bhabha, Peter J. Roy & Aaron W. Reinke. (2022) High-throughput small molecule screen identifies inhibitors of microsporidia invasion and proliferation in C. elegans. Nature Communications 13:1.
Crossref
Crossref
Yonghe Ding, Ke Du, Yu-Juan Niu, Yong Wang & Xiaolei Xu. (2022) Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity. Oxidative Medicine and Cellular Longevity 2022, pages 1-10.
Crossref
Crossref
Craig J. Beavers, Jo E. Rodgers, Aaron J. Bagnola, Theresa M. Beckie, Umberto Campia, Katherine E. Di Palo, Tochi M. Okwuosa, Eugene R. Przespolewski & Susan Dent. (2022) Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association. Circulation 145:15.
Crossref
Crossref
Yang Zhang, Qi Li, Dongsheng Xu, Tengteng Li, Zehui Gu, Peng Huang & Liqun Ren. (2021)
Idarubicin-induced oxidative stress and apoptosis in cardiomyocytes: An
in vitro
molecular approach
. Human & Experimental Toxicology 40:12_suppl, pages S553-S562.
Crossref
Crossref
Ragu Kanagasabai, Krishnamurthy Karthikeyan, Jay L. Zweier & Govindasamy Ilangovan. (2021) Serine mutations in overexpressed Hsp27 abrogate the protection against doxorubicin-induced p53-dependent cardiac apoptosis in mice. American Journal of Physiology-Heart and Circulatory Physiology 321:5, pages H963-H975.
Crossref
Crossref
He Cai, Hongbo Men, Pengyu Cao & Yang Zheng. (2021) Mechanism and prevention strategy of a bidirectional relationship between heart failure and cancer (Review). Experimental and Therapeutic Medicine 22:6.
Crossref
Crossref
Robin L. Jones, Andrew J. Wagner, Akira Kawai, Kazuo Tamura, Ashwin Shahir, Brian A. Van Tine, Javier Martín-Broto, Patrick M. Peterson, Jennifer Wright & William D. Tap. (2021) Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clinical Cancer Research 27:14, pages 3861-3866.
Crossref
Crossref
Cho-Won Kim & Kyung-Chul Choi. (2021) Effects of anticancer drugs on the cardiac mitochondrial toxicity and their underlying mechanisms for novel cardiac protective strategies. Life Sciences 277, pages 119607.
Crossref
Crossref
Anna Jirkovská, Galina Karabanovich, Jan Kubeš, Veronika Skalická, Iuliia Melnikova, Jan Korábečný, Tomáš Kučera, Eduard Jirkovský, Lucie Nováková, Hana Bavlovič Piskáčková, Josef Škoda, Martin Štěrba, Caroline A. Austin, Tomáš Šimůnek & Jaroslav Roh. (2021) Structure–Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions. Journal of Medicinal Chemistry 64:7, pages 3997-4019.
Crossref
Crossref
Dario Trapani, Paola Zagami, Eleonora Nicolò, Gabriella Pravettoni & Giuseppe Curigliano. (2020) Management of Cardiac Toxicity Induced by Chemotherapy. Journal of Clinical Medicine 9:9, pages 2885.
Crossref
Crossref
YanDong Zhang, ChengYuan Ma, ChunShui Liu & Feng Wei. (2020) Luteolin attenuates doxorubicin-induced cardiotoxicity by modulating the PHLPP1/AKT/Bcl-2 signalling pathway. PeerJ 8, pages e8845.
Crossref
Crossref
Jason Graffagnino, Lavanya Kondapalli, Garima Arora, Riem Hawi & Carrie G. Lenneman. (2020) Strategies to Prevent Cardiotoxicity. Current Treatment Options in Oncology 21:4.
Crossref
Crossref
Qi Li, Meng Qin, Qi Tan, Tengteng Li, Zehui Gu, Peng Huang & Liqun Ren. (2020)
MicroRNA‐129‐1‐3p protects cardiomyocytes from pirarubicin‐induced apoptosis by down‐regulating the GRIN2D‐mediated Ca
2+
signalling pathway
. Journal of Cellular and Molecular Medicine 24:3, pages 2260-2271.
Crossref
Crossref
Nadine Wenningmann, Merle Knapp, Anusha Ande, Tanaya R. Vaidya & Sihem Ait-Oudhia. (2019) Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring. Molecular Pharmacology 96:2, pages 219-232.
Crossref
Crossref
Raquel N. Rozner & William H. Frishman. (2019) Cardiovascular Effects of Chemotherapy Used in the Treatment of Breast Cancers. Cardiology in Review 27:2, pages 87-96.
Crossref
Crossref
Yang Zhang, Xiao-Yan Ma, Tong Zhang, Meng Qin, Bo Sun, Qi Li, Dian-Wen Hu & Li-Qun Ren. (2019)
Protective Effects of
Apocynum venetum
Against Pirarubicin-Induced Cardiotoxicity
. The American Journal of Chinese Medicine 47:05, pages 1075-1097.
Crossref
Crossref
Justine L. DelgadoChao-Ming Hsieh, Nei-Li Chan & Hiroshi Hiasa. (2018) Topoisomerases as anticancer targets. Biochemical Journal 475:2, pages 373-398.
Crossref
Crossref
Farzane Zarifi, Mahmoud Etebari & Abbas Jafarian- Dehkordi. (2018) Modulatory Effects of Dexrazoxane Against Genotoxicity and Lipid Peroxidation Induced by Idarubicin in HepG2 Cells. International Journal of Cancer Management 11:1.
Crossref
Crossref
Marjan Boerma. 2018. Gender Differences in the Pathogenesis and Management of Heart Disease. Gender Differences in the Pathogenesis and Management of Heart Disease
303
316
.
Alexandra Pender & Robin L Jones. (2017) Olaratumab for the treatment of soft-tissue sarcoma. Future Oncology 13:24, pages 2151-2157.
Crossref
Crossref
Tochi M Okwuosa, Sarah Anzevino & Ruta Rao. (2017) Cardiovascular disease in cancer survivors. Postgraduate Medical Journal 93:1096, pages 82-90.
Crossref
Crossref
Sara VandenwijngaertMelissa SwinnenAnn-Sophie WalravensManu BeerensHilde GillijnsEllen CaluwéRobert E. TainshDaniel I. NathanKaitlin AllenPeter BrouckaertJozef BartunekMarielle Scherrer-CrosbieKenneth D. BlochDonald B. BlochStefan P. JanssensEmmanuel S. Buys. (2017) Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice. Antioxidants & Redox Signaling 26:4, pages 153-164.
Crossref
Crossref
Vinodh Guvvala, Venkatesan Chidambaram Subramanian, Jayashree Anireddy & Mahesh Konda. (2016) Study on the Isolation and Chemical Investigation of Potential Impurities in Dexrazoxane Using 2D-NMR and LC-PDA-MS. Organic Process Research & Development 21:1, pages 11-17.
Crossref
Crossref
Enas M. Malik & Christa E. Müller. (2016) Anthraquinones As Pharmacological Tools and Drugs. Medicinal Research Reviews 36:4, pages 705-748.
Crossref
Crossref
Sabry M. Attia, Sheikh F. Ahmad, Quaiser Saquib, Gamaleldin I. Harisa, Abdulaziz A. Al-Khedhairy & Saleh A. Bakheet. (2016) Dexrazoxane mitigates epirubicin-induced genotoxicity in mice bone marrow cells. Mutagenesis 31:2, pages 137-145.
Crossref
Crossref
Carine E. HamoMichelle W. BloomDaniela CardinaleBonnie KyAnju NohriaLea BaerHal SkopickiDaniel J. LenihanMihai GheorghiadeAlexander R. LyonJaved Butler. (2016) Cancer Therapy–Related Cardiac Dysfunction and Heart Failure. Circulation: Heart Failure 9:2.
Crossref
Crossref
Robin K. Kuriakose, Rakesh C. Kukreja & Lei Xi. (2016) Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs. Oxidative Medicine and Cellular Longevity 2016, pages 1-9.
Crossref
Crossref
Richard M. Steingart, Howard Weinstein, John Sasso, Lee W. Jones, Michelle Johnson, Carol Chen, Jennifer Liu, Nancy Roistacher, Shawn C. Pun, Jonathan W. Weinsaft, Eileen McAleer, Dipti Gupta, Anthony Yu, Michael Baum & Wendy Schaffer. 2016. Clinical Cardio-Oncology. Clinical Cardio-Oncology
345
378
.
S. M. Attia, S. F. Ahmad & S. A. Bakheet. (2015) Impact of dexrazoxane on doxorubicin-induced aneuploidy in somatic and germinal cells of male mice. Cancer Chemotherapy and Pharmacology 77:1, pages 27-33.
Crossref
Crossref
M J Cross, B R Berridge, P J M Clements, L Cove-Smith, T L Force, P Hoffmann, M Holbrook, A R Lyon, H R Mellor, A A Norris, M Pirmohamed, J D Tugwood, J E Sidaway & B K Park. (2015) Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury. British Journal of Pharmacology 172:4, pages 957-974.
Crossref
Crossref
Linfeng Li, Adedoyin Abraham, Qiong Zhou, Hadi Ali, Jeremy O'Brien, Brayden Hamill, John Arcaroli, Wells Messersmith & Daniel LaBarbera. (2014) An Improved High Yield Total Synthesis and Cytotoxicity Study of the Marine Alkaloid Neoamphimedine: An ATP-Competitive Inhibitor of Topoisomerase IIα and Potent Anticancer Agent. Marine Drugs 12:9, pages 4833-4850.
Crossref
Crossref
Polina Sysa-Shah, Yi Xu, Xin Guo, Scott Pin, Djahida Bedja, Rachel Bartock, Allison Tsao, Angela Hsieh, Michael S. Wolin, An Moens, Venu Raman, Hajime Orita & Kathleen L. Gabrielson. (2014) Geranylgeranylacetone Blocks Doxorubicin-Induced Cardiac Toxicity and Reduces Cancer Cell Growth and Invasion through RHO Pathway Inhibition. Molecular Cancer Therapeutics 13:7, pages 1717-1728.
Crossref
Crossref
Onkar S. Bains, András Szeitz, Joanna M. Lubieniecka, Gina E. Cragg, Thomas A. Grigliatti, K. Wayne Riggs & Ronald E. Reid. (2013) A Correlation between Cytotoxicity and Reductase-Mediated Metabolism in Cell Lines Treated with Doxorubicin and Daunorubicin. Journal of Pharmacology and Experimental Therapeutics 347:2, pages 375-387.
Crossref
Crossref
Snezana K. Bjelogrlic, Silvana T. Lukic & Slavisa M. Djuricic. (2013)
Activity of Dexrazoxane and Amifostine Against Late Cardiotoxicity Induced by the Combination of Doxorubicin and Cyclophosphamide
In Vivo
. Basic & Clinical Pharmacology & Toxicology 113:4, pages 228-238.
Crossref
Crossref
Anat Rabinovich, Dana Weiss, Maya Weissman, Victor Novack & Itai Levi. (2012) Dexrazoxane does not affect treatment outcome in non‐Hodgkin's lymphoma patients. American Journal of Hematology 87:8, pages 830-832.
Crossref
Crossref
Angelo Carbone, Peter J. Psaltis, Adam J. Nelson, Robert Metcalf, James D. Richardson, Michael Weightman, Anthony Thomas, John W. Finnie, Glenn D. Young & Stephen G. Worthley. (2012) Dietary Omega-3 Supplementation Exacerbates Left Ventricular Dysfunction in an Ovine Model of Anthracycline-Induced Cardiotoxicity. Journal of Cardiac Failure 18:6, pages 502-511.
Crossref
Crossref
Rene Kizek, Vojtech Adam, Jan Hrabeta, Tomas Eckschlager, Svatopluk Smutny, Jaroslav V. Burda, Eva Frei & Marie Stiborova. (2012) Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances. Pharmacology & Therapeutics 133:1, pages 26-39.
Crossref
Crossref
Feifei Che, Yu Liu & Caigang Xu. (2011) Prevention and Treatment of Doxorubicin-Induced Cardiotoxicity by Dexrazoxane and Schisandrin B in Rabbits. International Journal of Toxicology 30:6, pages 681-689.
Crossref
Crossref
Steven E Lipshultz, Rebecca E Scully, Stuart R Lipsitz, Stephen E Sallan, Lewis B Silverman, Tracie L Miller, Elly V Barry, Barbara L Asselin, Uma Athale, Luis A Clavell, Eric Larsen, Albert Moghrabi, Yvan Samson, Bruno Michon, Marshall A Schorin, Harvey J Cohen, Donna S Neuberg, E John Orav & Steven D Colan. (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. The Lancet Oncology 11:10, pages 950-961.
Crossref
Crossref
W L Salzer, M Devidas, W L Carroll, N Winick, J Pullen, S P Hunger & B A Camitta. (2009) Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children's oncology group. Leukemia 24:2, pages 355-370.
Crossref
Crossref
Richard D. Olson & Barry J. Cusack. 2009. General, Applied and Systems Toxicology. General, Applied and Systems Toxicology.